EU Court upholds 40 mn euro fine on Lupin over Perindopril litigation

New Delhi: Drug maker Lupin Wednesday said a court in Europe has upheld a decision to impose a fine of 40 million euros (over Rs 325 crore) on the company by European Commission (EC) in a litigation over blood pressure lowering drug Perindopril. The Mumbai-based company said the General Court of the European Union has delivered its judgment concerning Lupin’s and other companies appeal against the EC 2014 decision in the Perindopril litigation.

“The General Court upheld the EC’s decision holding Lupin liable to pay a fine of euro 40 million,” the company said in a regulatory filing.

The company added that it will study the court’s judgment and evaluate further course of action.

In 2014, Lupin and Unichem Laboratories are among six global drug makers on which the European regulator had imposed a collective fine of 427.7 million euros for striking deals to prevent entry of cheaper version of blood pressure drug Perindopril in the EU.

Shares of the company Wednesday ended 1.62 per cent down at Rs 821.85 on the BSE.

  • Related Posts

    PGIMS recalls drug amid probe into deaths

    The PGIMS authorities have directed all departments to immediately stop using a specific batch of injectable Propofol, an anaesthetic drug, and return the available stock to the central store. The…

    NPPA list brings little relief: No price cut for 25% cancer drugs

    Mumbai: Nearly one in four cancer drug packs in a revised price list issued by the National Pharmaceutical Pricing Authority (NPPA) has seen no reduction in maximum retail price (MRP),…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    ZEN- G packs a punch in Organ Donation as Over 500 Students pledge Organs

    ZEN- G packs a punch in Organ Donation as Over 500 Students pledge Organs

    PGIMS recalls drug amid probe into deaths

    PGIMS recalls drug amid probe into deaths

    NPPA list brings little relief: No price cut for 25% cancer drugs

    NPPA list brings little relief: No price cut for 25% cancer drugs

    Centre Mandates Minimum One-Year Shelf Life For Imported Drugs

    Centre Mandates Minimum One-Year Shelf Life For Imported Drugs

    For Aakash Healthcare, Community People are Apples of its Eyes

    For Aakash Healthcare, Community People are Apples of its Eyes

    Not mandatory to recall stocks released to the market prior to implementation of TMR: NPPA

    Not mandatory to recall stocks released to the market prior to implementation of TMR: NPPA